Literature DB >> 21993885

Renal functional responses to selective intrarenal renin inhibition in Cyp1a1-Ren2 transgenic rats with ANG II-dependent malignant hypertension.

Catherine G Howard1, Kenneth D Mitchell.   

Abstract

Angiotensin (ANG) II-dependent hypertension is characterized by increases in intrarenal ANG II levels, derangement in renal hemodynamics, and augmented tubular sodium reabsorptive capability. Increased nephron expression of renin-angiotensin system components, such as angiotensinogen by proximal tubule cells and renin by collecting duct principal cells, has been associated with an augmented ability of the kidney to form ANG II in hypertensive states. However, the contribution of de novo intrarenal ANG II production to the development and maintenance of ANG II-dependent hypertension remains unclear. The present study was performed to determine the effects of selective intrarenal renin inhibition on whole kidney hemodynamics and renal excretory function in Cyp1a1-Ren2 rats with ANG II-dependent malignant hypertension in the absence of the confounding influence of associated reductions in mean arterial pressure (MAP). Male Cyp1a1-Ren2 transgenic rats were induced to develop malignant hypertension, anesthetized, and surgically prepared for intrarenal administration of the direct renin inhibitor aliskiren (0.01 mg/kg). Following acute aliskiren treatment, urine flow and sodium excretion increased (10.5 ± 1.1 to 15.9 ± 1.9 μl/min, P < 0.001; 550 ± 160 to 1,370 ± 320 neq/min, P < 0.001, respectively) and ANG II excretion decreased (120 ± 30 to 63 ± 17 fmol/h, P < 0.05). There were no significant changes in MAP, glomerular filtration rate, estimated renal plasma flow, plasma ANG II levels, or protein excretion. The present findings demonstrate that selective renal renin inhibition elicits diuretic and natriuretic responses in Cyp1a1-Ren2 rats with ANG II-dependent malignant hypertension. Elevated intraluminal ANG II levels likely act to augment tubular reabsorptive function and, thereby, contribute to the elevated blood pressure in Cyp1a1-Ren2 rats with ANG II-dependent malignant hypertension.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21993885      PMCID: PMC3251336          DOI: 10.1152/ajprenal.00187.2011

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  29 in total

1.  Enhanced urinary angiotensinogen excretion in Cyp1a1-Ren2 transgenic rats with inducible ANG II-dependent malignant hypertension.

Authors:  Carlo J Milani; Hiroyuki Kobori; John J Mullins; Kenneth D Mitchell
Journal:  Am J Med Sci       Date:  2010-11       Impact factor: 2.378

2.  Controlled hypertension, a transgenic toggle switch reveals differential mechanisms underlying vascular disease.

Authors:  S Kantachuvesiri; S Fleming; J Peters; B Peters; G Brooker; A G Lammie; I McGrath; Y Kotelevtsev; J J Mullins
Journal:  J Biol Chem       Date:  2001-07-11       Impact factor: 5.157

Review 3.  Intratubular renin-angiotensin system in hypertension.

Authors:  L Gabriel Navar; Hiroyuki Kobori; Minolfa C Prieto; Romer A Gonzalez-Villalobos
Journal:  Hypertension       Date:  2011-01-31       Impact factor: 10.190

4.  Direct renin inhibition with aliskiren normalizes blood pressure in Cyp1a1-Ren2 transgenic rats with inducible angiotensin ii-dependent malignant hypertension.

Authors:  Catherine G Howard; John J Mullins; Kenneth D Mitchell
Journal:  Am J Med Sci       Date:  2011-05       Impact factor: 2.378

Review 5.  New insights into the renoprotective actions of the renin inhibitor aliskiren in experimental renal disease.

Authors:  David L Feldman
Journal:  Hypertens Res       Date:  2010-03-05       Impact factor: 3.872

6.  AT1 receptor blockade prevents the increase in blood pressure and the augmentation of intrarenal ANG II levels in hypertensive Cyp1a1-Ren2 transgenic rats fed with a high-salt diet.

Authors:  Dustyn E Williams; Minolfa C Prieto; John J Mullins; L Gabriel Navar; Kenneth D Mitchell
Journal:  Am J Med Sci       Date:  2010-04       Impact factor: 2.378

Review 7.  Role of intracardiac renin-angiotensin-aldosterone system in extracellular matrix remodeling.

Authors:  P J Lijnen; V V Petrov
Journal:  Methods Find Exp Clin Pharmacol       Date:  2003-09

8.  Augmentation of endogenous intrarenal angiotensin II levels in Val5-ANG II-infused rats.

Authors:  Weijian Shao; Dale M Seth; L Gabriel Navar
Journal:  Am J Physiol Renal Physiol       Date:  2009-02-25

9.  Lack of cardiac fibrosis in a new model of high prorenin hyperaldosteronism.

Authors:  Jörg Peters; Torsten Schlüter; Thomas Riegel; Barbara S Peters; Andreas Beineke; Ulrike Maschke; Norbert Hosten; John J Mullins; Rainer Rettig
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-09-11       Impact factor: 4.733

Review 10.  The renin angiotensin system in the development of cardiovascular disease: role of aliskiren in risk reduction.

Authors:  Paolo Verdecchia; Fabio Angeli; Giovanni Mazzotta; Giorgio Gentile; Gianpaolo Reboldi
Journal:  Vasc Health Risk Manag       Date:  2008
View more
  8 in total

Review 1.  The role of the kidney in regulating arterial blood pressure.

Authors:  Hani M Wadei; Stephen C Textor
Journal:  Nat Rev Nephrol       Date:  2012-08-28       Impact factor: 28.314

Review 2.  Salt-Sensitive Hypertension: Perspectives on Intrarenal Mechanisms.

Authors:  Dewan S A Majid; Minolfa C Prieto; Luis Gabriel Navar
Journal:  Curr Hypertens Rev       Date:  2015

3.  Antihypertensive and renoprotective actions of soluble epoxide hydrolase inhibition in ANG II-dependent malignant hypertension are abolished by pretreatment with L-NAME.

Authors:  Zuzana Honetschlägerová; Kento Kitada; Zuzana Husková; Alexandra Sporková; Libor Kopkan; Marcela Bürgelová; Šárka Varcabová; Akira Nishiyama; Sung Hee Hwang; Bruce D Hammock; John D Imig; Herbert J Kramer; Petr Kujal; Zdenka Vernerová; Luděk Červenka
Journal:  J Hypertens       Date:  2013-02       Impact factor: 4.844

4.  Breeding Characteristics and Dose-dependent Blood Pressure Responses of Transgenic Cyp1a1-Ren2 Rats.

Authors:  Catherine J Leader; Barbara J Clark; Amber R Hannah; Ivan A Sammut; Gerard T Wilkins; Robert J Walker
Journal:  Comp Med       Date:  2018-09-05       Impact factor: 0.982

Review 5.  Intrarenal renin-angiotensin system in regulation of glomerular function.

Authors:  L Gabriel Navar
Journal:  Curr Opin Nephrol Hypertens       Date:  2014-01       Impact factor: 2.894

6.  Spironolactone mitigates, but does not reverse, the progression of renal fibrosis in a transgenic hypertensive rat.

Authors:  Catherine J Leader; Darren J Kelly; Ivan A Sammut; Gerard T Wilkins; Robert J Walker
Journal:  Physiol Rep       Date:  2020-05

7.  Myocardial global longitudinal strain: An early indicator of cardiac interstitial fibrosis modified by spironolactone, in a unique hypertensive rat model.

Authors:  Catherine J Leader; Mohammed Moharram; Sean Coffey; Ivan A Sammut; Gerard W Wilkins; Robert J Walker
Journal:  PLoS One       Date:  2019-08-12       Impact factor: 3.240

8.  The effect of spironolactone on cardiac and renal fibrosis following myocardial infarction in established hypertension in the transgenic Cyp1a1Ren2 rat.

Authors:  C J Leader; G T Wilkins; R J Walker
Journal:  PLoS One       Date:  2021-11-29       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.